Cracking the Code of Resistance across Multiple Lines of ALK Inhibitor Therapy in Lung Cancer.

Qiao H, Lovly CM
Cancer Discov. 2016 6 (10): 1084-1086

PMID: 27698100 · PMCID: PMC5117458 · DOI:10.1158/2159-8290.CD-16-0910

In the setting of recent exciting clinical results and numerous ongoing trials, Gainor and colleagues explored mechanisms of acquired resistance to first- and second-generation ALK inhibitors in ALK-rearranged non-small cell lung cancer and found that an increased frequency and distinct spectrums of resistance mutations emerged with the more potent second-generation inhibitors. Their findings have important and immediate clinical implications as the resistance mutations detected impart differential sensitivities to available ALK inhibitors, thereby highlighting the need for sequential biopsies with molecular testing to determine the most effective treatment strategy upon disease progression. Cancer Discov; 6(10); 1084-6. ©2016 AACRSee related article by Gainor et al., p. 1118.

©2016 American Association for Cancer Research.

MeSH Terms (8)

Carcinoma, Non-Small-Cell Lung Drug Resistance, Neoplasm Humans Lung Neoplasms Protein Kinase Inhibitors Pyrazoles Pyridines Receptor Protein-Tyrosine Kinases

Connections (1)

This publication is referenced by other Labnodes entities: